sponsored
PatientsVille.com Logo

PatientsVille

Lumigan Medical Research Studies

Up-to-date List of Lumigan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lumigan Medical Research Studies

Rank Status Study
1 Recruiting Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Conditions: Primary Open Angle Glaucoma;   Ocular Hypertension
Interventions: Drug: Monoprost;   Drug: Lumigan 0.01%;   Drug: Lumigan 0.03% Unit Dose
Outcome Measures: safety with respect to the assessment of conjunctival hyperaemia in the Worse eye;   Response to treatment
2 Unknown  Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma
Conditions: Ocular Hypertension;   Primary Glaucoma
Interventions: Drug: Latanoprost, bimatoprost, travoprost;   Drug: travoprost, latanoprost and bimatoprost
Outcome Measure: intraocular pressure
3 Recruiting Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Conditions: Open-Angle Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost ophthalmic formulation A;   Drug: bimatoprost ophthalmic formulation B;   Drug: bimatoprost ophthalmic formulation C;   Drug: bimatoprost ophthalmic formulation D;   Drug: bimatoprost ophthalmic formulation E;   Drug: bimatoprost ophthalmic formulation F;   Drug: Sham;   Drug: timolol 0.5%;   Drug: bimatoprost ophthalmic solution 0.03%;   Drug: latanoprost 0.005%;   Drug: timolol vehicle (placebo)
Outcome Measures: Stage 1: Change from Baseline in Intraocular Pressure (IOP);   Stage 2: Change from Baseline in IOP;   Stage 2: IOP;   Time to Escape Treatment;   Time to Second Injection
4 Recruiting Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost 0.01% ophthalmic solution;   Drug: bimatoprost 0.03% ophthalmic solution
Outcome Measures: Percentage of Patients Reporting One or More Treatment-Related Ocular Surface Adverse Events;   Percentage of Patients Reporting One or More Treatment-Related Ocular Surface Adverse Events excluding "Conjunctival Hyperemia"
5 Recruiting A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: Bimatoprost 0.01%;   Drug: Bimatoprost 0.03%
Outcome Measure: Percentage of Patients with an Increase in Macroscopic Conjunctival Hyperemia
6 Recruiting An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost 0.01%;   Drug: travatan 0.004%;   Drug: timolol 0.5%;   Drug: hypromellose 0.3%
Outcome Measure: Intraocular Pressure (IOP) in the Study Eye
7 Recruiting Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost 0.01%;   Drug: travoprost 0.004%;   Drug: timolol 0.5%;   Drug: hypromellose 0.3%
Outcome Measure: Intraocular Pressure (IOP) in the Study Eye
8 Not yet recruiting Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants
Conditions: Alopecia;   Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution;   Drug: placebo
Outcome Measures: Measuring regrowth of eyebrows and eyelashes by Bimatoprost Opthalmic solution;   Effectiveness of Bimatoprost Ophthalmic Solution as assessed by patient self-report on a scale of 0-4.;   Psychological impact as assessed at baseline and at 6 months by patient-completed questionnaires
9 Recruiting A Study of Bimatoprost 0.01% in the Clinical Setting
Conditions: Glaucoma, Primary Open Angle;   Ocular Hypertension
Intervention: Drug: Bimatoprost 0.01%
Outcome Measures: Percentage of Patients With Ocular Hyperemia;   Change from Baseline in Intraocular Pressure (IOP);   Percentage of Patients Who Discontinue Due to an Adverse Event
10 Recruiting Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: Preservative-free latanoprost;   Drug: Preservative-free bimatoprost
Outcome Measures: Difference in mean IOP values between the 2 groups at 6 months;   Difference in IOP values IOP values, visual acuity, hyperaemia, visual acuity and tolerability between the groups in change from baseline
11 Recruiting A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
Condition: Glaucoma
Interventions: Drug: bimatoprost ophthalmic solution formulation A;   Drug: timolol ophthalmic solution;   Drug: bimatoprost vehicle
Outcome Measures: Change from Baseline in Intraocular Pressure (IOP);   Percentage of Patients with a 15% Decrease in IOP
12 Not yet recruiting Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
Condition: Graves' Ophthalmopathy
Interventions: Drug: Bimatoprost;   Drug: Eye drop solution
Outcome Measures: The primary endpoint of this study will be comparison of the change in ophthalmometry readings over the two 3 month treatment periods.;   Change in quality of life scores on the TED quality of life questionnaire (GO-QOL);   Intraocular pressures;   Side effects;   Health economic outcomes
13 Recruiting Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows
Condition: Hypotrichosis
Interventions: Drug: Track A;   Drug: Track B
Outcome Measures: One grade improvement at week 16, 24 and 36 as based on the IGEA;   Grade improvement based on IEA4 at week 16, 24 and 36
14 Recruiting Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
Condition: Glaucoma
Intervention:
Outcome Measure: Tolerability of medications as measured by the COMTOL validated instrument
15 Not yet recruiting Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
Condition: Thyroid Associated Ophthalmopathies
Intervention: Drug: bimatoprost 0.03%
Outcome Measures: Bimatoprost effect on soft tissue amount and exophthalmos in inactive TED patients.;   Number of participants with adverse events.
16 Recruiting A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Conditions: Glaucoma, Primary Open Angle;   Ocular Hypertension
Intervention: Drug: Fixed Combination Bimatoprost and Timolol
Outcome Measures: Change from Baseline in Intraocular Pressure (IOP) in the Study Eye;   Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale;   Patient Assessment of Tolerability on a 4-Point Scale;   Physician Assessment of Tolerability on a 4-Point Scale;   Percentage of Patients who Discontinue Treatment;   Percentage of Patients Prescribed by the Physician to Continue Treatment;   Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
17 Not yet recruiting The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
Conditions: Thyroid Eye Disease;   Ocular Hypertension;   Glaucoma
Interventions: Drug: Prostaglandin Analog;   Drug: Timolol
Outcome Measures: Change from baseline in appearance of facial periorbital region at 12 months.;   Change from baseline in Hertel exophthalmometry at 12 and 24 months.;   Change from baseline in intraocular pressure at 12 and 24 months.;   Change from baseline in appearance of facial periorbital region at 24 months.
18 Unknown  Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves
Condition: Glaucoma
Intervention: Drug: Aqueous Suppressant Eye Drops
Outcome Measures: Intraocular pressure;   Hyperencapsulation phase (HEP);   Qualified Ahmed Glaucoma Valve success;   Absolute Ahmed Glaucoma Valve success;   Number of glaucoma medications
19 Recruiting Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy);   Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Outcome Measures: Intraocular Pressure (IOP);   IOP

These studies may lead to new treatments and are adding insight into Lumigan etiology and treatment.

A major focus of Lumigan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lumigan